Literature DB >> 19473410

Health-related quality of life and productivity impact in haemophilia patients with inhibitors.

T M Brown1, W C Lee, A V Joshi, C L Pashos.   

Abstract

To measure health-related quality of life (HRQL), its determinants, and its association with patient and caregiver productivity among a sample of haemophilia patients with inhibitors in the United States (US). Data on demographical and clinical characteristics, treatment patterns, HRQL (SF-12v2), and productivity outcomes were reported for 53 patients. Mean SF-12v2 domain and mental (MCS) and physical (PCS) component summary scores were assessed and compared with US norms. Regression analyses explored the association of patient and treatment factors with HRQL and productivity. Patients' mean age was 20.7 years (SD = 18.8), 88.5% were type A, and 39.6% received on-demand therapy as their only mode of treatment. Mean PCS was significantly lower than the US norm (PCS, 39.9, P < 0.01) and mean MCS showed no significant difference (MCS, 49.9, P = ns). On-demand treatment (B = -0.336, P < 0.05) and number of haemorrhages (B = -0.366, P < 0.05) were negatively associated with PCS; and PCS was associated with patients' missed work or school days [incidence rate ratio (IRR) = 0.93, P < 0.001] and perceived impact on daily activities (OR = 0.72, P < 0.05). Younger age (IRR = 0.91, P < 0.01), lower PCS (IRR = 0.94, P < 0.01), more haemorrhages (IRR = 1.05, P < 0.05), and surgery (IRR = 2.74, P < 0.05) were associated with fewer patients' productive days. Physical functioning among inhibitor patients in the US is compromised and is negatively associated with their daily activities and productivity. These data suggest a positive association of prophylactic and immunotolerance therapy with HRQL, specifically physical impairment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473410     DOI: 10.1111/j.1365-2516.2009.02032.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  11 in total

1.  Longitudinal changes in health-related quality of life for chronic diseases: an example in hemophilia A.

Authors:  Jiat-Ling Poon; Jason N Doctor; Michael B Nichol
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

2.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

3.  The 12-item medical outcomes study short form health survey version 2.0 (SF-12v2): a population-based validation study from Tehran, Iran.

Authors:  Ali Montazeri; Mariam Vahdaninia; Sayed Javad Mousavi; Mohsen Asadi-Lari; Sepideh Omidvari; Mahmoud Tavousi
Journal:  Health Qual Life Outcomes       Date:  2011-03-07       Impact factor: 3.186

4.  The effect of yoga on the quality of life in the children and adolescents with haemophilia.

Authors:  Noushin Beheshtipoor; Shahapar Bagheri; Fatemeh Hashemi; Najaf Zare; Mehran Karimi
Journal:  Int J Community Based Nurs Midwifery       Date:  2015-04

Review 5.  Optimal management of hemophilic arthropathy and hematomas.

Authors:  Sébastien Lobet; Cedric Hermans; Catherine Lambert
Journal:  J Blood Med       Date:  2014-10-17

6.  Cardiac surgery in patients with Hemophilia:is it safe?

Authors:  Amjad Shalabi; Erez Kachel; Alexander Kogan; Leonid Sternik; Liza Grosman-Rimon; Ronny Ben-Avi; Diab Ghanem; Eilon Ram; Ehud Raanani; Mudi Misgav
Journal:  J Cardiothorac Surg       Date:  2020-05-08       Impact factor: 1.637

7.  Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Authors:  Chatree Chai-Adisaksopha; Mark W Skinner; Randall Curtis; Neil Frick; Michael B Nichol; Declan Noone; Brian O'Mahony; David Page; Jeffrey Stonebraker; Lehana Thabane; Mark Crowther; Alfonso Iorio
Journal:  BMJ Open       Date:  2018-08-08       Impact factor: 2.692

Review 8.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

Review 9.  Importance of immune response genes in hemophilia A.

Authors:  Josiane Bazzo de Alencar; Luciana Conci Macedo; Morgana Ferreira de Barros; Camila Rodrigues; Renata Campos Cadide; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 10.  Physical and psychosocial challenges in adult hemophilia patients with inhibitors.

Authors:  Sue duTreil
Journal:  J Blood Med       Date:  2014-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.